Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2018, Article ID 8659826, 7 pages
https://doi.org/10.1155/2018/8659826
Research Article

Functional Parameters of 18F-FDG PET/CT in Patients with Primary Testicular Diffuse Large B-Cell Lymphoma

1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
2West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
3Department of Pathology, West China Hospital, Sichuan University, Chengdu, China

Correspondence should be addressed to Xuelei Ma; moc.liamg@ieleuxamrd

Received 11 April 2018; Revised 21 July 2018; Accepted 3 September 2018; Published 27 September 2018

Guest Editor: Elena Bonanno

Copyright © 2018 Jing Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. B. Moller, F. d’Amore, and B. E. Christensen, “Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis, The Danish Lymphoma Study Group, LYFO,” European Journal of Cancer, vol. 30, no. 12, pp. 1760–1764, 1994. View at Google Scholar
  2. J. D. Gundrum, M. A. Mathiason, D. B. Moore, and R. S. Go, “Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab,” Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 27, no. 31, pp. 5227–5232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Y. Cheah, A. Wirth, and J. F. Seymour, “Primary testicular lymphoma,” Blood, vol. 123, no. 4, pp. 486–493, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. G. Lantz, N. Power, B. Hutton, and R. Gupta, “Malignant lymphoma of the testis: a study of 12 cases,” Canadian Urological Association Journal, vol. 3, no. 5, pp. 393–398, 2009. View at Google Scholar
  5. N. Verma, J. Lazarchick, V. Gudena, J. Turner, and U. B. Chaudhary, “Testicular lymphoma: an update for clinicians,” American Journal of the Medical Sciences, vol. 336, no. 4, pp. 336–341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Hernandez-Maraver, F. Hernandez-Navarro, N. Gomez-Leon et al., “Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma,” British Journal of Haematology, vol. 135, no. 3, pp. 293–302, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Mansi, V. Cuccurullo, and R. Grassi, “Diagnostic imaging and pathology,” in Advanced Imaging Techniques in Clinical Pathology, F. M. Sacerdoti, A. Giordano, and C. Cavaliere, Eds., pp. 107–111, Springer New York, New York, NY, USA, 2016. View at Google Scholar
  8. K. Pak, G. J. Cheon, K. W. Kang, J. K. Chung, E. E. Kim, and D. S. Lee, “Prognostic value of SUVmean in oropharyngeal and hypopharyngeal cancers: comparison with SUVmax and other volumetric parameters of 18F-FDG PET,” Clin Nucl Med, vol. 40, no. 1, pp. 9–13, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Rubello, P. Gordien, C. Morliere et al., “Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma,” Clinical Nuclear Medicine, vol. 40, no. 8, pp. e405–e410, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Sher, F. Lacoeuille, P. Fosse et al., “For avid glucose tumors, the SUV peak is the most reliable parameter for (18)FFDG-PET/CT quantification, regardless of acquisition time,” EJNMMI Research, vol. 6, no. 1, pp. 016–0177, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Wang, “PET/CT: appropriate application in lymphoma,” Chinese Clinical Oncology, vol. 4, no. 1, pp. 2304–3865, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. N. G. Schaefer, T. F. Hany, C. Taverna et al., “Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?” Radiology, vol. 232, no. 3, pp. 823–829, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Moog, M. Bangerter, C. G. Diederichs et al., “Extranodal malignant lymphoma: detection with FDG PET versus CT,” Radiology, vol. 206, no. 2, pp. 475–481, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Bednaruk-Mlynski, J. Pienkowska, A. Skorzak et al., “Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma,” Leukemia and Lymphoma, vol. 56, no. 2, pp. 377–382, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Ishiwata, M. Tomura, T. Ido, R. Iwata, J. Itoh, and M. Kameyama, “In vivo assessment of 6-deoxy-6-18Ffluoro-D-galactose as a PET tracer for studying galactose metabolism,” International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, vol. 16, no. 8, pp. 775–781, 1989. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Mena, M. L. Lindenberg, B. I. Turkbey et al., “A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy,” Clinical Nuclear Medicine, vol. 39, no. 10, pp. 874–881, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. A. T. Ilica, K. Kocacelebi, R. Savas, and A. Ayan, “Imaging of extranodal lymphoma with PET/CT,” Clinical Nuclear Medicine, vol. 36, no. 10, pp. e127–e138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Karunanithi, P. Sharma, S. G. Roy et al., “Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma,” Clinical Nuclear Medicine, vol. 39, no. 9, pp. 772–776, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Buskirk, R. G. Evans, P. M. Banks, M. J. O’Connell, and J. D. Earle, “Primary lymphoma of the testis,” International Journal of Radiation Oncology∗Biology∗Physics, vol. 8, no. 10, pp. 1699–1703, 1982. View at Publisher · View at Google Scholar · View at Scopus
  20. S. S. Ahmad, S. F. Idris, G. A. Follows, and M. V. Williams, “Primary testicular lymphoma,” Clinical Oncology, vol. 24, no. 5, pp. 358–365, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Schoder, A. Noy, M. Gonen et al., “Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 23, no. 21, pp. 4643–4651, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Kosuda, S. Fisher, P. V. Kison, R. L. Wahl, and H. B. Grossman, “Uptake of 2-deoxy-2-18Ffluoro-D-glucose in the normal testis: retrospective PET study and animal experiment,” Annals of Nuclear Medicine, vol. 11, no. 3, pp. 195–199, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Kitajima, Y. Nakamoto, M. Senda, Y. Onishi, H. Okizuka, and K. Sugimura, “Normal uptake of 18F-FDG in the testis: an assessment by PET/CT,” Annals of Nuclear Medicine, vol. 21, no. 7, pp. 405–410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Shao, Q. Gao, X. W. Tian, S. Y. Wang, C. H. Liang, and S. X. Wang, “Differentiation and diagnosis of benign and malignant testicular lesions using 18F-FDG PET/CT,” European Journal of Radiology, vol. 93, pp. 114–120, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Khiewvan, P. Ziai, S. Houshmand, A. Salavati, P. Ziai, and A. Alavi, “The role of PET/CT as a prognosticator and outcome predictor in lung cancer,” Expert Review of Respiratory Medicine, vol. 10, no. 3, pp. 317–330, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. S. H. Hwang, A. Cho, M. Yun, Y. D. Choi, S. Y. Rha, and W. J. Kang, “Prognostic value of pretreatment metabolic tumor volume and total lesion glycolysis using 18F-FDG PET/CT in patients with metastatic renal cell carcinoma treated with anti-vascular endothelial growth factor-targeted agents,” Clinical Nuclear Medicine, vol. 42, no. 5, pp. e235–e241, 2017. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Castelli, A. Depeursinge, B. de Bari et al., “Metabolic tumor volume and total lesion glycolysis in oropharyngeal cancer treated with definitive radiotherapy: which threshold is the best predictor of local control?” Clin Nucl Med, vol. 42, no. 6, pp. e281–e285, 2017. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Lim, A. Eaton, N. Y. Lee et al., “18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma,” Journal of Nuclear Medicine, vol. 53, no. 10, pp. 1506–1513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Moskowitz, H. Schoder, S. Gavane et al., “Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma,” Blood, vol. 130, no. 20, pp. 2196–2203, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Xie, W. Zhai, S. Cheng, H. Zhang, Y. Xie, and W. He, “Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma,” Hematology, vol. 21, no. 2, pp. 99–105, 2016. View at Publisher · View at Google Scholar · View at Scopus